Full Text of PDF (361k)
Article in Japanese
Abstract
Case Report
A case of HER2-mutation-positive locally advanced non-small cell lung cancer treated with durvalumab after chemoradiotherapy
Yuko Sasaki Hisashi Tanaka Tomonori Makiguchi Yuri Kobori Haruka Odagiri Sadatomo Tasaka
Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine
ABSTRACT
Consolidation therapy with durvalumab after chemoradiotherapy has been standard treatment for patients with stage III, locally advanced non-small cell lung cancer (NSCLC). However, there have been few reports about its efficacy for patients with driver mutations. Notably, it remains unclear whether durvalumab is effective for patients with locally advanced NSCLC harboring HER2 mutation.
A 65-year-old female was referred to our hospital because of an abnormal shadow on her chest roentgenogram. We made a diagnosis of adenocarcinoma (cT2aN3M0, Stage IIIB) and treated the patient with definitive chemoradiotherapy followed by durvalumab for one year. After 15 months, she developed disease recurrence. After the sixth-line treatment, she died 3 years and 3 months after the start of durvalumab treatment.
KEYWORDS
HER2 exon 20 insertion mutation Non-small cell lung cancer (NSCLC) Immune checkpoint inhibitor (ICI) Durvalumab
Received 25 May 2022 ／ Accepted 13 Jul 2022
AJRS, 11(5): 310-314, 2022
Copyright © The Japanese Respiratory Society All Rights Reserved.